iHCK-37

SKU: orb2813907

Description

iHCK-37 (ASN05260065) is a selective Hck inhibitor that blocks HIV-1 replication and exhibits antitumor activity. It suppresses erythropoietin-induced PI3K/AKT and MAPK/ERK signaling in high Hck-expressing cells, making it a useful research tool for studying chronic myelogenous leukemia (CML) in vitro.

Research Area

Cardiovascular Research, Signal Transduction

Key Properties

• CAS Number: 516478-09-4
• MW: 544.73
• Purity: 99.97% (May vary between batches)
• Formula: C₃₀H₃₂N₄O₂S₂
• SMILES: O=C(NC=1C=CC=CC1N2CCOCC2)CSC=3N=C(N=C4SC5=C(C43)CCCC5)CCC=6C=CC=CC6
• Target: Hck,Src
• Solubility: DMSO:200 mg/mL (367.15 mM)

Bioactivity

• Target IC50:
  Hck:0.22 μM (Ki)
• In Vitro:
  Methods: AML cell lines (HL60, KG1a and U937) and chronic myeloid leukemia cell lines (HEL and K562) were treated with iHCK-37 (5.0-20 μM, 24 hours) and cell viability was detected. Results: iHCK-37 showed effective antiproliferative activity in vitro, with growth inhibition (GI50) of 5.0-5.8 μM for AML cell lines (HL60, KG1a and U937) and 9.1-19.2 μM for chronic myeloid leukemia cell lines (HEL and K562). Methods: Lentivirus HCK-silenced K562 and U937 cell lines and KG1a (AML/CD34+) cell lines were treated with iHCK-37 (3-9 μM) and protein level changes were detected by WB. Results: iHCK-37 led to decreased phosphorylation of ERK, AKT, and P70S6K in lentiviral HCK-silenced K562 and U937 cell lines; and decreased p-HCK, p-ERK, p-AKT, and p-70S6 in the KG1a (AML/CD34+) cell line in a concentration-dependent manner.

Storage & Handling

• Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

ASN05260065, ASN-05260065, ASN 05260065, iHCK 37, iHCK37, iHCK-37

Compound Identifiers

PubChem CID

3197505